scholarly journals Radical Cystectomies at the University Teaching Hospital, Lusaka: Baseline Characteristics, Short-term Complications, and Role of Nursing Care

2021 ◽  
Vol 7 (1) ◽  
pp. 1-4
Author(s):  
Nkomba Chamileke
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Common Cancer ◽  
Role Of Nursing ◽  
Muscle Invasive

Bladder cancer is the ninth most common cancer in the world and the 11th most common cancer in Zambia. Bladder cancer is of three histological types, Squamous cell cancer, Transitional cell cancer, and Adenocarcinoma. The most common histological type in Zambia is Squamous cell cancer accounting for 60 percent of cases of muscle-invasive bladder cancer. The treatment of muscle-invasive bladder cancer is radical cystectomy, Lymph node dissection, and urinary diversion. Globally, radical cystectomy is associated with high morbidity and mortality. The most common diversion used was uretero-sigmoidostomy, accounting for 60 percent of cases. In our case series, the most common complications were wound dehiscence, hypo-proteinemia, bowel ileus, deep vein thrombosis, and electrolyte imbalance. Identification and prevention of complications associated with this procedure play a crucial role in improving survival for these patients. The role of nursing staff in the early recognition of these complications cannot be overemphasized.

480 The staging role of 18FDG PET-CT in patients with muscle-invasive bladder cancer selected for radical cystectomy

2013 ◽  
Vol 12 (1) ◽  
pp. e480
Author(s):  
M.C. Ferriero ◽  
G. Simone ◽  
R. Papalia ◽  
S. Guaglianone ◽  
R. Sciuto ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Muscle Invasive

Neoadjuvant accelerated MVAC therapy in bladder cancer: toxicity and efficacy correlation

2015 ◽  
Vol 3 (4) ◽  
pp. 582-594
Author(s):  
William M. Grabstald ◽  
Richard H. Sarkis ◽  
Chrisophos A. Jacobus ◽  
Smith V. Feifer
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Cancer Staging ◽  
Invasive Disease ◽  
Fourth Edition ◽  
Muscle Invasive Bladder Cancer ◽  
Common Cancer ◽  
Node Metastases ◽  
Grade 3 ◽  
Muscle Invasive

Bladder cancer is the second most common cancer of the genitourinary tract. Radical cystectomy is considered the gold standard of treatment for patients with localized muscle-invasive disease (MIBC), although chemoradiotherapy protocols using neoadjuvant cisplatin-based chemotherapy is used for muscle-invasive bladder cancer. We explored the toxicity and efficacy of neoadjuvant AMVAC in MIBC. A total of 177 patients with clinical tumor–node–metastases (TNM) stage T2N0M0 to T4aN0M0 bladder cancer who were candidates for radical cystectomy were eligible, tumors were staged according to the criteria in the fourth edition of the American Joint Committee on Cancer staging manual. Grade ≥ 2 toxicities were observed in 8% of patients, with grade 3 and 4 neutropenia in 7% and 5% patients, respectively; grade 3 and 4 anemia in 4% and 2% of patients, respectively; no patients died of drug toxicity; 61% of patients were accrued; 16% were down-staged to non–muscle invasive disease. Further, 31% showing pT0 at cystectomy and the median survival was 16.9 months.

Systemic therapy and overall survival trends in patients with non-urothelial histologic variants of muscle invasive bladder cancer undergoing radical cystectomy.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 376-376 ◽  
Author(s):  
Shreyas Joshi ◽  
Elizabeth Handorf ◽  
Andres Correa ◽  
Alexander Kutikov ◽  
Benjamin T. Ristau ◽  
...  
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Survival Benefit ◽  
Cox Regression ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Kaplan Meier ◽  
Muscle Invasive

376 Background: Histological variants of urothelial carcinoma (UC) of the bladder have a poorer prognosis than histologically pure UC, and the role of neoadjuvant chemotherapy (NAC) in this group is unclear. Our objective was to evaluate NAC practice patterns and survival outcomes in patients with histologic variants undergoing radical cystectomy (RC). Methods: Patients with cT2-4N0-3M0 muscle invasive bladder cancer (MIBC) who underwent RC from 2003-2012 were selected from the National Cancer Database (NCDB). Patients were categorized by histology code as pure UC or histologic variants. Adjusting for patient and clinical characteristics, generalized estimating equations were used to test the association between histology and receipt of NAC. The association between receipt of NAC and overall survival (OS) was evaluated using Kaplan Meier curves and Cox regression models. Results: In 19,976 patients meeting inclusion criteria, receipt of NAC in histologic variants was less (11-14%) than in pure UC (22%), with the exception of micropapillary disease (23%) (Table). Median OS was lower in variant histologies than for pure UC (8.4 – 30.2 vs. 37.6 months). Receipt of NAC was associated with improved survival compared to RC or RC+adjuvant chemotherapy in patients with pure UC (HR 0.91, p=0.0016). There was no evidence of a survival benefit for NAC in the variant histologies, or that treatment effects differed by histology (P-val for interaction=0.84). Conclusions: In the NCDB, a substantial proportion of patients (13%) with histologic variants of MIBC undergoing RC receive NAC in the absence of a proven survival benefit. Clinical trials inclusive of patients with variant histologies are necessary to elucidate the role of NAC prior to RC. [Table: see text]

1434 THE STAGING ROLE OF 18FDG PET-CT IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER SELECTED FOR RADICAL CYSTECTOMY

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Mariaconsiglia Ferriero ◽  
Giuseppe Simone ◽  
Rocco Papalia ◽  
Salvatore Guaglianone ◽  
Rosa Sciuto ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Muscle Invasive

Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.

1998 ◽  
Vol 16 (4) ◽  
pp. 1601-1612 ◽  
Author(s):  
M A Dimopoulos ◽  
L A Moulopoulos
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Carcinoma ◽  
Disease Free Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Muscle Invasive ◽  
Disease Free

PURPOSE The standard treatment for patients with muscle-invasive carcinoma of the urinary bladder is radical cystectomy. While radical cystectomy cures many patients with this tumor, almost 50% of them will develop metastatic disease. Adjuvant chemotherapy has been proposed for these patients in an attempt to reduce the probability of relapse and to improve survival. To assess whether adjuvant chemotherapy does benefit patients with muscle-invasive bladder cancer, we reviewed all phase II and III studies published in the English literature over the last 20 years. METHODS A review of all published reports was facilitated by the use of Medline computer search and by manual search of the Index Medicus. RESULTS Several comparative, nonrandomized studies have indicated that adjuvant chemotherapy may prolong disease-free survival. Four randomized studies have been conducted and all had a suboptimal patient accrual. Three studies used a cisplatin-containing combination chemotherapy and included primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder. All three studies indicated that adjuvant chemotherapy improved disease-free survival and two of them also showed improvement in event-free survival and overall survival, respectively. CONCLUSION Published series have been unable to establish an undisputed benefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder cancer. The interpretation of the available data is compromised by several methodologic and statistical problems. Thus, adjuvant chemotherapy cannot be considered as a standard treatment for all patients with muscle-invasive carcinoma of the bladder. Well-designed prospective randomized studies are needed to clarify the role of adjuvant chemotherapy in this disease. However, outside a protocol setting, there is some evidence that patients with extravesical disease or with lymph node involvement may benefit from adjuvant treatment with cisplatin-based combination chemotherapy. No data support such an approach for patients with muscle-invasive but organ-confined bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document